The procalcitonin (PCT) assay market size is projected to be worth US$ 280.6 million in 2023. The market is likely to surpass US$ 512.9 million by 2033 at a CAGR of 6.2% during the forecast period. Growing lung cancer incidences is aiding the market growth. The PCT assay market has seen significant growth in recent years due to the increasing awareness about the importance of early and accurate diagnosis of bacterial infections The Procalcitonin (PCT) assay refers to the market for diagnostic tests that measure the levels of procalcitonin in the bloodstream. Procalcitonin is a precursor protein to the hormone calcitonin and is produced in response to bacterial infections.
Other Drivers Propelling the Demand for Procalcitonin (PCT) Assay Market include:
Challenges for Companies /Manufacturers in the Procalcitonin (PCT) Assay Market:
Opportunities in the Procalcitonin (PCT) Assay Market Industry:
Latest Trends in the Procalcitonin (PCT) Assay Market:
| Attributes | Details |
|---|---|
| Procalcitonin (PCT) Assay Market Size (2023) | US$ 280.6 million |
| Procalcitonin (PCT) Assay Market Projected Size (2033) | US$ 512.9 million |
| Value CAGR (2023 to 2033) | 6.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global procalcitonin (PCT) assay market experienced a CAGR of 3.0%, reaching a market size of US$ 280.6 million in 2023.
The global procalcitonin (PCT) assay market witnessed steady growth in the past and is expected to continue to develop at a significant pace due to their increasing demand in non-hospital settings, such as primary care clinics and outpatient facilities. The increasing availability of PCT testing options, including point-of-care devices, facilitates broader access to PCT testing and supports early diagnosis and appropriate management of bacterial infections in various healthcare settings.
With the rising concern of antibiotic resistance, there is an increased emphasis on antibiotic stewardship programs. PCT assays play a vital role in these programs by assisting clinicians in determining the need for antibiotic therapy, optimizing treatment duration, and monitoring response to treatment. This is also leading to enhanced integration of PCT testing into antibiotic stewardship protocols.
Future Forecast for Procalcitonin (PCT) Assay Market Industry:
Looking ahead, the global procalcitonin (PCT) assay market is expected to rise at a CAGR of 6.2% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 512.9 million by 2033.
PCT is increasingly being used as part of biomarker panels or algorithms to improve the accuracy of infection diagnosis and prognosis. Combining PCT with other biomarkers, such as C-reactive protein (CRP) or proadrenomedullin (MR-proADM), can provide a more comprehensive assessment of the severity and course of an infection, this could likely increase the sales of PCT assays in the coming times.
Collaboration between diagnostic companies, assay manufacturers, and healthcare providers is becoming more prevalent. Partnerships and collaborations among manufactures will combine expertise, resources, and technologies to develop innovative PCT assays, improve accessibility, and expand market reach. These partnerships can lead to the development of integrated diagnostic solutions and improved patient care.
| Country | The United States |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 202.0 million |
| CAGR % 2023 to End of Forecast (2033) | 7.3% |
The procalcitonin (PCT) assay market in the United States is expected to reach a market size of US$ 202.0 million by 2033, expanding at a CAGR of 7.3%. The United States has been experiencing a rising incidence of bacterial infections, including community-acquired pneumonia, sepsis, and urinary tract infections. This has heightened the need for accurate and timely diagnosis to guide appropriate treatment decisions. PCT assays offer valuable insights for differentiating bacterial from viral infections, aiding in the diagnosis and management of these conditions.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 26.4 million |
| CAGR % 2023 to End of Forecast (2033) | 8.3% |
The procalcitonin (PCT) assay market in the United Kingdom is expected to reach a market value of US$ 26.4 million, expanding at a CAGR of 8.3% during the forecast period. The availability of favorable reimbursement policies for PCT testing has played a role in the market growth of PCT assays in the UK. Reimbursement coverage by public and private payers incentivizes healthcare providers to adopt and utilize PCT assays, ensuring proper compensation for the testing services provided.
| Country | China |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 62.7 million |
| CAGR % 2023 to End of Forecast (2033) | 9.1% |
The procalcitonin (PCT) assay market in China is anticipated to reach a market size of US$ 62.7 million by the end of 2033, growing at a CAGR of 9.1% throughout the forecast period. There has been a significant increase in awareness among healthcare professionals in China about the clinical utility and benefits of PCT testing. Educational initiatives, conferences, and scientific publications have contributed to the dissemination of knowledge regarding PCT assays and their role in infection management. This improved awareness has led to increased demand for PCT assays in the country.
| Country | Japan |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 20.8 million |
| CAGR % 2023 to End of Forecast (2033) | 6.7% |
The procalcitonin (PCT) assay market in Japan is estimated to reach a market size of US$ 20.8 million by 2033, expected to thrive at a CAGR of 6.7%. Technological advancements have improved the accessibility and efficiency of PCT assays. Automated platforms, rapid testing options, and point-of-care devices have made PCT testing more convenient and streamlined in various healthcare settings. These advancements have facilitated the integration of PCT assays into routine clinical practice, leading to their surge in the Japan.
| Country | South Korea |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 13.9 million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The procalcitonin (PCT) assay market in South Korea is expected to reach a market size of US$ 13.9 million, expanding at a CAGR of 6.0% during the forecast period. South Korea has a robust healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories. This infrastructure supports the implementation and utilization of PCT assays in routine practice. The presence of well-equipped healthcare facilities and the availability of trained personnel contribute to the increased demand for PCT assays in the country.
Principal Consultant
Serum sample dominated the procalcitonin (PCT) assay market with a market share of 34.2% in 2022. Collecting serum samples is a routine and minimally invasive procedure. Blood samples can be easily obtained through venipuncture and processed to separate serum and plasma from other blood components. This simplicity and familiarity make serum a convenient sample type for PCT assay testing.
Based on products, test kits have dominated the category withholding the significant share of the market at around 68.7% at the end of 2022. Test kits for PCT assays are readily available in the market from multiple manufacturers. This wide availability ensures that laboratories and healthcare facilities have access to a variety of options, allowing them to select the test kit that best fits their specific requirements in terms of performance, cost, and workflow compatibility.
By purpose, clinical use segment is expected to continue leading the market over a CAGR of 6.0% throughout the projected timeframe. PCT assays have proven clinical utility in the diagnosis of bacterial infections, especially severe infections such as sepsis. PCT levels in the bloodstream rise significantly in response to bacterial infections, making it a valuable biomarker for differentiating bacterial from viral infections. This diagnostic value has led to the widespread adoption of PCT assays in clinical practice for guiding antibiotic therapy and supporting clinical decision-making.
The hospitals have led the procalcitonin (PCT) assay market as the leading end user with the market share of 36.7% in 2022. Hospitals are primary providers of acute care, dealing with a wide range of patients, including those with severe infections, sepsis, and other critical conditions. PCT assays have significant clinical utility in these settings, aiding in the diagnosis, monitoring, and management of bacterial infections. Hospitals rely on PCT assays to support clinical decision-making, guide antibiotic therapy, and assess patient prognosis in these acute care scenarios.
By employing these strategies, key players in the PCT assay market can enhance their competitiveness, differentiate their offerings, and maintain a strong market presence. Continuous innovation, strategic partnerships, effective marketing, and customer-centric approaches are crucial for sustained success in this competitive industry.
Key Strategies Used by the Participants
Key players continuously invest in research and development to introduce innovative PCT assay products. They strive to develop assays with improved sensitivity, specificity, accuracy, and ease of use.
Key players often form strategic partnerships and collaborations with other companies, research institutions, and healthcare organizations. These partnerships can lead to knowledge sharing, joint product development, and expanded market reach.
Expanding into emerging markets with growing healthcare infrastructure and rising demand for PCT assays allows companies to tap into new opportunities and gain a competitive edge.
Companies in the market may engage in mergers or acquisitions to streamline their product portfolio, obtain new technologies, enter new market niches, and gain access to novel products or intellectual property.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Procalcitonin (PCT) Assay Market:
The global procalcitonin (PCT) assay market is expected to reach a valuation of US$ 280.6 million by 2023.
The procalcitonin (PCT) assay market demand is set to expand by 6.2% during the assessment period.
The test kits segment is projected to hold the dominant share of the market.
The market is predicted to exceed US$ 512.9 million by 2033.
The North America offers key opportunities for new entrants in the procalcitonin (PCT) assay market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation/Development Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis, by Region 4.2. New Product Launches 4.3. Regulatory Landscape, By Country 4.4. PESTEL Analysis 4.5. Porter’s Five Force Analysis 4.6. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Immunoassay Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increasing Incidence of Sepsis and Infectious Diseases 5.2.2. Growing Emphasis on Antibiotic Stewardship 5.2.3. Increasing Awareness about PCT as a Biomarker 5.2.4. Continuous Advancements in Assay Technologies, Including Immunoassays, Molecular Diagnostics, and Point-Of-Care Testing 5.2.5. Expansion into Non-Hospital Settings 5.2.6. Investments in Research and Development 5.2.7. Emerging Markets and Increased Healthcare Spending 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunities 6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Volume (Units) Analysis, 2012 to 2022 6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market Demand Pricing Analysis 2012 to 2022 and Forecast, 2023 to 2033 7.1. Regional Pricing Analysis 7.2. Pricing Break-up 7.2.1. Manufacturer Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033 8.1. Revenue Opportunity Scenario- Likely/Conservative/Optimistic 8.2. Historical Market Value (US$ Million) Analysis, 2012 to 2022 8.3. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 8.3.1. Y-o-Y Growth Trend Analysis 8.3.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Sample Type, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sample Type, 2023 to 2033 9.3.1. Serum 9.3.2. Plasma 9.3.3. Cell Culture Medium 9.3.4. Other Biological Fluids 9.4. Market Attractiveness Analysis By Sample Type 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) and Volume (Unit) By Product, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033 10.3.1. Test Kits 10.3.1.1. Procalcitonin ELISA test kits 10.3.1.2. Procalcitonin CLIA kits 10.3.1.3. PCT Immunochromatography KITS 10.3.1.4. PCT Rapid Test Kit 10.3.2. Analyzer & Instrument 10.3.3. Consumable 10.4. Market Attractiveness Analysis By Product 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Purpose 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Purpose, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Purpose, 2023 to 2033 11.3.1. Clinical Use 11.3.2. Research Use Only 11.4. Market Attractiveness Analysis By Purpose 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 12.3.1. Hospital 12.3.2. Specialty Clinics 12.3.3. Academic and Research Institute 12.3.4. Diagnostics Laboratories 12.4. Market Attractiveness Analysis By End User 13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Region, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. South Asia 13.3.5. East Asia 13.3.6. Oceania 13.3.7. Middle East & Africa 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. USA 14.3.1.2. Canada 14.3.2. By Sample Type 14.3.3. By Product 14.3.4. By Purpose 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Sample Type 14.4.3. By Product 14.4.4. By Purpose 14.4.5. By End User 14.5. Market Trends 14.6. Market Drivers & Restraints – Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. USA Market 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Sample Type 14.7.1.2.2. By Product 14.7.1.2.3. By Purpose 14.7.1.2.4. By End User 14.7.2. Canada Market 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Sample Type 14.7.2.2.2. By Product 14.7.2.2.3. By Purpose 14.7.2.2.4. By End User 15. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Brazil 15.3.1.2. Mexico 15.3.1.3. Argentina 15.3.1.4. Rest of LATAM 15.3.2. By Sample Type 15.3.3. By Product 15.3.4. By Purpose 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Sample Type 15.4.3. By Product 15.4.4. By Purpose 15.4.5. By End User 15.5. Market Trends 15.6. Market Drivers & Restraints – Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. Brazil Market 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Sample Type 15.7.1.2.2. By Product 15.7.1.2.3. By Purpose 15.7.1.2.4. By End User 15.7.2. Mexico Market 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Sample Type 15.7.2.2.2. By Product 15.7.2.2.3. By Purpose 15.7.2.2.4. By End User 15.7.3. Argentina Market 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Sample Type 15.7.3.2.2. By Product 15.7.3.2.3. By Purpose 15.7.3.2.4. By End User 16. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. UK 16.3.1.2. Germany 16.3.1.3. France 16.3.1.4. Italy 16.3.1.5. Spain 16.3.1.6. BENELUX 16.3.1.7. Russia 16.3.1.8. Rest of Europe 16.3.2. By Sample Type 16.3.3. By Product 16.3.4. By Purpose 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Sample Type 16.4.3. By Product 16.4.4. By Purpose 16.4.5. By End User 16.5. Market Trends 16.6. Market Drivers & Restraints – Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. UK Market 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Sample Type 16.7.1.2.2. By Product 16.7.1.2.3. By Purpose 16.7.1.2.4. By End User 16.7.2. Germany Market 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Sample Type 16.7.2.2.2. By Product 16.7.2.2.3. By Purpose 16.7.2.2.4. By End User 16.7.3. France Market 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Sample Type 16.7.3.2.2. By Product 16.7.3.2.3. By Purpose 16.7.3.2.4. By End User 16.7.4. Italy Market 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Sample Type 16.7.4.2.2. By Product 16.7.4.2.3. By Purpose 16.7.4.2.4. By End User 16.7.5. Spain Market 16.7.5.1. Introduction 16.7.5.2. Market Analysis and Forecast by Market Taxonomy 16.7.5.2.1. By Sample Type 16.7.5.2.2. By Product 16.7.5.2.3. By Purpose 16.7.5.2.4. By End User 16.7.6. BENELUX Market 16.7.6.1. Introduction 16.7.6.2. Market Analysis and Forecast by Market Taxonomy 16.7.6.2.1. By Sample Type 16.7.6.2.2. By Purpose 16.7.6.2.3. By Product 16.7.6.2.4. By End User 16.7.7. Russia Market 16.7.7.1. Introduction 16.7.7.2. Market Analysis and Forecast by Market Taxonomy 16.7.7.2.1. By Sample Type 16.7.7.2.2. By Product 16.7.7.2.3. By Purpose 16.7.7.2.4. By End User 17. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Sample Type 17.3.3. By Product 17.3.4. By Purpose 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Sample Type 17.4.3. By Product 17.4.4. By Purpose 17.4.5. By End User 17.5. Market Trends 17.6. Market Drivers & Restraints – Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. China Market 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Sample Type 17.7.1.2.2. By Product 17.7.1.2.3. By Purpose 17.7.1.2.4. By End User 17.7.2. Japan Market 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Sample Type 17.7.2.2.2. By Product 17.7.2.2.3. By Purpose 17.7.2.2.4. By End User 17.7.3. South Korea Market 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Sample Type 17.7.3.2.2. By Product 17.7.3.2.3. By Purpose 17.7.3.2.4. By End User 18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Indonesia 18.3.1.3. Thailand 18.3.1.4. Malaysia 18.3.1.5. Rest of South Asia 18.3.2. By Sample Type 18.3.3. By Product 18.3.4. By Purpose 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Sample Type 18.4.3. By Product 18.4.4. By Purpose 18.4.5. By End User 18.5. Market Trends 18.6. Market Drivers & Restraints – Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. India Market 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Sample Type 18.7.1.2.2. By Product 18.7.1.2.3. By Purpose 18.7.1.2.4. By End User 18.7.2. Indonesia Market 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Sample Type 18.7.2.2.2. By Product 18.7.2.2.3. By Purpose 18.7.2.2.4. By End User 18.7.3. Thailand Market 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Sample Type 18.7.3.2.2. By Product 18.7.3.2.3. By Purpose 18.7.3.2.4. By End User 18.7.4. Malaysia Market 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast by Market Taxonomy 18.7.4.2.1. By Sample Type 18.7.4.2.2. By Product 18.7.4.2.3. By Purpose 18.7.4.2.4. By End User 19. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Sample Type 19.3.3. By Product 19.3.4. By Purpose 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Sample Type 19.4.3. By Product 19.4.4. By Purpose 19.4.5. By End User 19.5. Market Trends 19.6. Market Drivers & Restraints – Impact Analysis 19.7. Country Level Analysis & Forecast 19.7.1. Australia Market 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Sample Type 19.7.1.2.2. By Product 19.7.1.2.3. By Purpose 19.7.1.2.4. By End User 19.7.2. New Zealand Market 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Sample Type 19.7.2.2.2. By Product 19.7.2.2.3. By Purpose 19.7.2.2.4. By End User 20. Middle East & Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022 20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Türkiye 20.3.1.3. South Africa 20.3.1.4. Northern Africa 20.3.1.5. Rest of Middle East and Africa 20.3.2. By Sample Type 20.3.3. By Product 20.3.4. By Purpose 20.3.5. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Sample Type 20.4.3. By Product 20.4.4. By Purpose 20.4.5. By End User 20.5. Market Trends 20.6. Market Drivers & Restraints – Impact Analysis 20.7. Country Level Analysis & Forecast 20.7.1. GCC Countries Market 20.7.1.1. Introduction 20.7.1.2. Market Analysis and Forecast by Market Taxonomy 20.7.1.2.1. By Sample Type 20.7.1.2.2. By Product 20.7.1.2.3. By Purpose 20.7.1.2.4. By End User 20.7.2. Türkiye Market 20.7.2.1. Introduction 20.7.2.2. Market Analysis and Forecast by Market Taxonomy 20.7.2.2.1. By Sample Type 20.7.2.2.2. By Product 20.7.2.2.3. By Purpose 20.7.2.2.4. By End User 20.7.3. South Africa Market 20.7.3.1. Introduction 20.7.3.2. Market Analysis and Forecast by Market Taxonomy 20.7.3.2.1. By Sample Type 20.7.3.2.2. By Product 20.7.3.2.3. By Purpose 20.7.3.2.4. By End User 20.7.4. Northern Africa Market 20.7.4.1. Introduction 20.7.4.2. Market Analysis and Forecast by Market Taxonomy 20.7.4.2.1. By Sample Type 20.7.4.2.2. By Product 20.7.4.2.3. By Purpose 20.7.4.2.4. By End User 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies (Maternity Care Types) 21.2. Market Share Analysis of Top Players 21.3. Market Concentration 22. Competition Analysis 22.1. Competition Dashboard 22.2. Branding and Promotional Strategies, By key Players 22.3. Key Development Analysis 22.4. Competition Deep Dive 22.4.1. Thermo Fisher Scientific Inc. 22.4.1.1. Overview 22.4.1.2. Type Portfolio 22.4.1.3. Key Financials 22.4.1.4. SWOT Analysis 22.4.1.5. Key Developments 22.4.1.6. Sales Footprint 22.4.1.7. Strategy Overview 22.4.1.7.1. Marketing Strategy 22.4.1.7.2. Type Strategy 22.4.1.7.3. Channel Strategy 22.4.2. J. Mitra & Co. Pvt. Ltd. 22.4.2.1. Overview 22.4.2.2. Type Portfolio 22.4.2.3. Key Financials 22.4.2.4. SWOT Analysis 22.4.2.5. Key Developments 22.4.2.6. Sales Footprint 22.4.2.7. Strategy Overview 22.4.2.7.1. Marketing Strategy 22.4.2.7.2. Type Strategy 22.4.2.7.3. Channel Strategy 22.4.3. Thermo Fisher Scientific Inc. 22.4.3.1. Overview 22.4.3.2. Type Portfolio 22.4.3.3. Key Financials 22.4.3.4. SWOT Analysis 22.4.3.5. Key Developments 22.4.3.6. Sales Footprint 22.4.3.7. Strategy Overview 22.4.3.7.1. Marketing Strategy 22.4.3.7.2. Type Strategy 22.4.3.7.3. Channel Strategy 22.4.4. Elabscience Biotechnology Inc. 22.4.4.1. Overview 22.4.4.2. Type Portfolio 22.4.4.3. Key Financials 22.4.4.4. SWOT Analysis 22.4.4.5. Key Developments 22.4.4.6. Sales Footprint 22.4.4.7. Strategy Overview 22.4.4.7.1. Marketing Strategy 22.4.4.7.2. Type Strategy 22.4.4.7.3. Channel Strategy 22.4.5. CUSABIO TECHNOLOGY LLC 22.4.5.1. Overview 22.4.5.2. Type Portfolio 22.4.5.3. Key Financials 22.4.5.4. SWOT Analysis 22.4.5.5. Key Developments 22.4.5.6. Sales Footprint 22.4.5.7. Strategy Overview 22.4.5.7.1. Marketing Strategy 22.4.5.7.2. Type Strategy 22.4.5.7.3. Channel Strategy 22.4.6. Wuhan Fine Biotech Co., Ltd. 22.4.6.1. Overview 22.4.6.2. Type Portfolio 22.4.6.3. Key Financials 22.4.6.4. SWOT Analysis 22.4.6.5. Key Developments 22.4.6.6. Sales Footprint 22.4.6.7. Strategy Overview 22.4.6.7.1. Marketing Strategy 22.4.6.7.2. Type Strategy 22.4.6.7.3. Channel Strategy 22.4.7. Company ABclonal, Inc. 22.4.7.1. Overview 22.4.7.2. Type Portfolio 22.4.7.3. Key Financials 22.4.7.4. SWOT Analysis 22.4.7.5. Key Developments 22.4.7.6. Sales Footprint 22.4.7.7. Strategy Overview 22.4.7.7.1. Marketing Strategy 22.4.7.7.2. Type Strategy 22.4.7.7.3. Channel Strategy 22.4.8. Nanjing Vazyme Biotech Co.,Ltd. 22.4.8.1. Overview 22.4.8.2. Type Portfolio 22.4.8.3. Key Financials 22.4.8.4. SWOT Analysis 22.4.8.5. Key Developments 22.4.8.6. Sales Footprint 22.4.8.7. Strategy Overview 22.4.8.7.1. Marketing Strategy 22.4.8.7.2. Type Strategy 22.4.8.7.3. Channel Strategy 22.4.9. RayBiotech Life, Inc. 22.4.9.1. Overview 22.4.9.2. Type Portfolio 22.4.9.3. Key Financials 22.4.9.4. SWOT Analysis 22.4.9.5. Key Developments 22.4.9.6. Sales Footprint 22.4.9.7. Strategy Overview 22.4.9.7.1. Marketing Strategy 22.4.9.7.2. Type Strategy 22.4.9.7.3. Channel Strategy 22.4.10. Hipro Biotechnology Co.,Ltd. 22.4.10.1. Overview 22.4.10.2. Type Portfolio 22.4.10.3. Key Financials 22.4.10.4. SWOT Analysis 22.4.10.5. Key Developments 22.4.10.6. Sales Footprint 22.4.10.7. Strategy Overview 22.4.10.7.1. Marketing Strategy 22.4.10.7.2. Type Strategy 22.4.10.7.3. Channel Strategy 22.4.11. Vitrosens Biotechnology 22.4.11.1. Overview 22.4.11.2. Type Portfolio 22.4.11.3. Key Financials 22.4.11.4. SWOT Analysis 22.4.11.5. Key Developments 22.4.11.6. Sales Footprint 22.4.11.7. Strategy Overview 22.4.11.7.1. Marketing Strategy 22.4.11.7.2. Type Strategy 22.4.11.7.3. Channel Strategy 22.4.12. bioMérieux SA 22.4.12.1. Overview 22.4.12.2. Type Portfolio 22.4.12.3. Key Financials 22.4.12.4. SWOT Analysis 22.4.12.5. Key Developments 22.4.12.6. Sales Footprint 22.4.12.7. Strategy Overview 22.4.12.7.1. Marketing Strategy 22.4.12.7.2. Type Strategy 22.4.12.7.3. Channel Strategy 22.4.13. ELK Biotechnology CO.,Ltd. 22.4.13.1. Overview 22.4.13.2. Type Portfolio 22.4.13.3. Key Financials 22.4.13.4. SWOT Analysis 22.4.13.5. Key Developments 22.4.13.6. Sales Footprint 22.4.13.7. Strategy Overview 22.4.13.7.1. Marketing Strategy 22.4.13.7.2. Type Strategy 22.4.13.7.3. Channel Strategy 22.4.14. Immuno-Biological Laboratories, Inc. 22.4.14.1. Overview 22.4.14.2. Type Portfolio 22.4.14.3. Key Financials 22.4.14.4. SWOT Analysis 22.4.14.5. Key Developments 22.4.14.6. Sales Footprint 22.4.14.7. Strategy Overview 22.4.14.7.1. Marketing Strategy 22.4.14.7.2. Type Strategy 22.4.14.7.3. Channel Strategy 22.4.15. BISAF 22.4.15.1. Overview 22.4.15.2. Type Portfolio 22.4.15.3. Key Financials 22.4.15.4. SWOT Analysis 22.4.15.5. Key Developments 22.4.15.6. Sales Footprint 22.4.15.7. Strategy Overview 22.4.15.7.1. Marketing Strategy 22.4.15.7.2. Type Strategy 22.4.15.7.3. Channel Strategy 22.4.16. Roche Diagnostics 22.4.16.1. Overview 22.4.16.2. Type Portfolio 22.4.16.3. Key Financials 22.4.16.4. SWOT Analysis 22.4.16.5. Key Developments 22.4.16.6. Sales Footprint 22.4.16.7. Strategy Overview 22.4.16.7.1. Marketing Strategy 22.4.16.7.2. Type Strategy 22.4.16.7.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Procalcitonin (PCT) Assay Market
